Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours

Cancer Chemotherapy and Pharmacology

Volumn 48, Issue 5, 2001, Pages 361-369

  Bos, A M E ^a   De Vries, E G E ^a   Dombernovsky, P ^b   Aamdal, S ^c   Uges, D R A ^a   Schrijvers, D ^d   Wanders, J ^e   Roelvink, M W J ^e   Hanauske, A R ^f   Bortini, S ^g   Capriati, A ^g   Crea, A E G ^g   Vermorken, J B ^d  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Mental Health Services CPH   (Denmark)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f I Med Klinik   (Netherlands)

^g Menarini Ricerche SpA   (Netherlands)

Author keywords

Anthracycline; Pharmacokinetics; Phase I; Solid tumours

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; DOXORUBICIN; EPIRUBICIN; SABARUBICIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG URINE LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT; URINARY EXCRETION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHILD; DISACCHARIDES; DOXORUBICIN; FEMALE; HUMANS; KIDNEY; MALE; MIDDLE AGED; NEOPLASMS;

EID: 0034764701     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800100350     Document Type: Article

References (29)

1. The anthracyclines: Will we ever find a better doxorubicin?
2. Ring-B modified anthracyclines
3. Relationship between activity and amino sugar stereochemistry of daunorubicin and adriamycin derivatives
4. DNA topoisomerase II as the primary target of antitumor anthracyclines
5. Joint experimental and theoretical investigations of the comparative DNA binding affinities of intercalating anthracycline derivatives
6. Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicity
7. Influence of structural modifications at the 3′ and 4′ positions of doxorubicin on the drug ability to trap topoisomerase II and to overcome multidrug resistance
8. New anthracycline disaccharides: Synthesis of L-daunosaminyl-α(1→4)-2-deoxy-L-rhamnosyl and of L-daunosaminyl-α(1→4)-2-deoxy-L-fucosyl daunorubicin analogues
9. Doxorubicin disaccharide analogue: Apoptosis-related improvement of efficacy in vivo
10. Improved efficacy and enlarged spectrum of activity of a novel anthracycline disaccharide analogue of doxorubicin against human tumor xenografts
11. Comparison of doxorubicin- and MEN 10755-induced long-term progressive cardiotoxicity in the rat
12. Phase I and pharmacokinetic study of MEN-10755 in solid tumors
13. Phase I study to determine the safety of MEN-10755 in patients with a solid tumor on a short i.v. infusion given once every 3 weeks
14. MW/PHARM, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring
15. Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study
16. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans
17. Epirubicin. Clinical pharmacology and dose-effect relationship
18. Pharmacokinetics and metabolism of anthracyclines
19. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy
20. Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer
21. Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer
22. Comparative pharmacokinetic study of Adriamycin and 4′-epi-adriamycin after their simultaneous intravenous administration